SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rosetta Inpharmatics (RSTA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: greedsgd_2000 who started this subject11/30/2000 8:54:11 AM
From: nigel bates  Read Replies (2) of 31
 
Nov. 30, 2000-- Rosetta Inpharmatics, Inc. (Nasdaq:RSTA - news) today announced that it has entered into an agreement with Abbott Laboratories (NYSE:ABT - news) to investigate the molecular basis of toxicity of a wide range of different compounds in animal and human liver model systems.
By combining Rosetta's expertise in bioinformatics, the Rosetta FlexJet(TM) DNA Microarray Platform, and the Rosetta Resolver(TM) Expression Data Analysis product with Abbott's extensive capabilities in toxicological sciences, the two companies will create a proprietary database for toxicology analysis. Each company will fund their own respective efforts under the collaboration.
The collaboration will create gene expression profiles for a portfolio of recognized compounds that result in toxic responses in both animals and humans. These compounds will provide an important reference to accurately predict the toxicity of compounds with therapeutic potential using gene expression profiles. It will also provide important information concerning differences in the response between animal and human liver systems.
Using the knowledge derived from the collaboration, the companies will develop translation algorithms thereby enabling the prediction of human responses using animal models or cell lines.
This collaboration enables Rosetta to build fundamental patterns that are prerequisites to our ongoing collaborative work with Abbott and other partners. The application of these technologies will allow the rapid analysis of gene expression patterns providing researchers with an efficient and cost-effective means to predict potential toxicity of drug candidates earlier in the drug development cycle than could be obtained using standard methods....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News